Palvella Therapeutics, Inc. (PVLA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.89B USD. 52-week range 65.93 to 161.38 USD. Data as of 2026-10-09.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the ...